FindTrial
Sign In

Long-term study of TA-8317 in patients with cancer breakthrough pain

Long-term study of TA-8317 in patients with cancer breakthrough pain

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220302
Enrollment
Unknown
Registered
2006-10-02
Start date
2006-10-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer breakthrough pain

Interventions

investigational material(s) Generic name etc : TA-8317 (Fentanyl (INN)) INN of investigational material : Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Investigati

Sponsors

Tanabe Pharma Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (Inclusion criteria) Patients who are 20 years old or older. Patients who are diagnosed and notified to have cancer. Patients who are treated for persistent cancer pain with opioid analgesics, but experience breakthrough pain , etc. (Exclusion criteria) Patient's performance status scale (PS) is grade 4. Patients with moderate to severe stomatitis , etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety and Efficacy (Pain relief score etc)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026